POMC and hyperaldosteronism: By inhibiting CYP17, it also reduces cortisol synthesis, leading to stimulation of adrenocorticotropic hormone (ACTH) and a shift in steroidogenesis toward aldosterone synthesis This process may lead to secondary hyperaldosteronism.